Literature DB >> 18612258

Effectiveness of Medifast supplements combined with obesity pharmacotherapy: a clinical program evaluation.

C K Haddock1, W S C Poston, J P Foreyt, J J DiBartolomeo, P O Warner.   

Abstract

PURPOSE: To evaluate the long-term impact of Medifast meal-replacement supplements (MMRS) combined with appetite suppressant medication (ASM) among participants who received 52 weeks of treatment.
METHODS: We conducted a systematic program evaluation of weight loss data from a medically-supervised weight control program combining the use of MMRS and ASM. Data were obtained and analyzed from 1,351 patient (BMI> or =25) medical charts who had participated for at least 12 weeks of treatment. Outcomes included weight loss (kg) and percent weight loss from baseline and at 12, 24, and 52 weeks. Both completers and intention-to-treat analyses were conducted. Completers' (i.e., those with complete data for 52 weeks) outcomes were evaluated after stratification for reported adherence to the MMRS and ASM.
RESULTS: Participants who completed 52 weeks of treatment experienced substantial weight losses at 12 (-9.4+/-5.7 kg), 24 (-12.0+/-8.1 kg), and 52 weeks (-12.4+/-9.2 kg) and all measures were significantly different from baseline weight (p<0.001 for all contrasts) for both true completers (n=324) and for ITT analysis (n=1,351). Fifty percent of patients remained in the program at 24 weeks and nearly 25% were still participating at one year.
CONCLUSIONS: This weight loss program using a combination of MMRS and ASM produced significant and sustained weight losses at 52 weeks. Results were better than those typically reported for obesity pharmacotherapy in both short- and long-term studies and also better than those reported for partial meal replacement programs. Program retention at one year was similar to that reported in many controlled drug trials and better than most commercial programs reported in the literature.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18612258     DOI: 10.1007/BF03327609

Source DB:  PubMed          Journal:  Eat Weight Disord        ISSN: 1124-4909            Impact factor:   4.652


  11 in total

1.  Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials.

Authors:  C K Haddock; W S C Poston; P L Dill; J P Foreyt; M Ericsson
Journal:  Int J Obes Relat Metab Disord       Date:  2002-02

2.  What consumers want to know about commercial weight-loss programs: a pilot investigation.

Authors:  Shirley S Wang; Thomas A Wadden; Leslie G Womble; Cathy A Nonas
Journal:  Obes Res       Date:  2003-01

3.  Retention rates and weight loss in a commercial weight loss program.

Authors:  C E Finley; C E Barlow; F L Greenway; C L Rock; B J Rolls; S N Blair
Journal:  Int J Obes (Lond)       Date:  2006-06-06       Impact factor: 5.095

4.  Randomised controlled trial of four commercial weight loss programmes in the UK: initial findings from the BBC "diet trials".

Authors:  Helen Truby; Sue Baic; Anne deLooy; Kenneth R Fox; M Barbara E Livingstone; Catherine M Logan; Ian A Macdonald; Linda M Morgan; Moira A Taylor; D Joe Millward
Journal:  BMJ       Date:  2006-05-23

Review 5.  Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials.

Authors:  R Padwal; S K Li; D C W Lau
Journal:  Int J Obes Relat Metab Disord       Date:  2003-12

6.  Randomized trial of lifestyle modification and pharmacotherapy for obesity.

Authors:  Thomas A Wadden; Robert I Berkowitz; Leslie G Womble; David B Sarwer; Suzanne Phelan; Robert K Cato; Louise A Hesson; Suzette Y Osei; Rosalind Kaplan; Albert J Stunkard
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

7.  Weight loss with self-help compared with a structured commercial program: a randomized trial.

Authors:  Stanley Heshka; James W Anderson; Richard L Atkinson; Frank L Greenway; James O Hill; Stephen D Phinney; Ronette L Kolotkin; Karen Miller-Kovach; F Xavier Pi-Sunyer
Journal:  JAMA       Date:  2003-04-09       Impact factor: 56.272

8.  Weight management using a meal replacement strategy: meta and pooling analysis from six studies.

Authors:  S B Heymsfield; C A J van Mierlo; H C M van der Knaap; M Heo; H I Frier
Journal:  Int J Obes Relat Metab Disord       Date:  2003-05

Review 9.  Systematic review: an evaluation of major commercial weight loss programs in the United States.

Authors:  Adam Gilden Tsai; Thomas A Wadden
Journal:  Ann Intern Med       Date:  2005-01-04       Impact factor: 25.391

10.  High attrition rates in commercial weight reduction programs.

Authors:  F R Volkmar; A J Stunkard; J Woolston; R A Bailey
Journal:  Arch Intern Med       Date:  1981-03
View more
  3 in total

1.  RE: Pulmonary hypertension associated with use of phentermine?

Authors:  Ed J Hendricks; Richard B Rothman
Journal:  Yonsei Med J       Date:  2011-09       Impact factor: 2.759

2.  Pharmacotherapy for Obesity and Changes in Eating Behavior: a Patient and Physician's Perspective.

Authors:  Piper L Miguelgorry; Ed J Hendricks
Journal:  Adv Ther       Date:  2016-05-31       Impact factor: 3.845

Review 3.  Off-label drugs for weight management.

Authors:  Ed J Hendricks
Journal:  Diabetes Metab Syndr Obes       Date:  2017-06-10       Impact factor: 3.168

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.